Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Ponderano – page 15

276 clinical trials in Ponderano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ponderano at a glance
276
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

276 trials in Ponderano

Open in trial search

Paresis

Not recruiting

Study on the Effectiveness and Safety of NT 201 (Botulinum Toxin) for Treating Lower Limb Spasticity in Adults After Stroke or Traumatic Brain Injury

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Merz Pharmaceuticals GmbH

Study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia and TP53 Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Ospedale San Raffaele S.r.l.

Study on Ibrutinib and Venetoclax for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Ospedale San Raffaele S.r.l.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Universita' Degli Studi Di Torino

Study on Loncastuximab Tesirine for Patients with Relapsed or Refractory Mantle Cell Lymphoma After Immunochemotherapy with Rituximab, Bendamustine, and Cytarabine

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Loncastuximab Tesirine
  • Sponsor:Fondazione Italiana Linfomi Ets

Study on Preventing Respiratory Issues from RSV Bronchiolitis in Preterm Babies Using Palivizumab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Palivizumab
  • Sponsor:Azienda Sanitaria Locale Della Provincia Di Biella

Plasma cell myeloma

Not recruiting

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Fo.Ne.Sa. Fondazione Neoplasie Sangue Ets

Breast cancer stage III+2

Not recruiting

Study on Restoring Immunotherapy Sensitivity in Advanced Triple Negative Breast Cancer Using Ceralasertib, Durvalumab, and Paclitaxel Albumin-Bound

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets

Study on Early vs. Delayed Ticagrelor with Cangrelor for Patients with STEMI Undergoing PCI

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ticagrelor
  • Sponsor:Azienda Ospedaliero-Universitaria Maggiore Della Carita

Mantle cell lymphoma

Not recruiting

Study on Rituximab, Bendamustine, Cytarabine, and Venetoclax for High-Risk Elderly Patients with Mantle Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Italiana Linfomi Ets

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Ponderano

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancer types, including colorectal cancer, lymphoma, and endometrial cancer. Studies evaluate novel therapeutic combinations and personalized treatment approaches.

  • Advanced Pancreatic Cancer Treatment
  • Lymphoma Therapy Optimization
  • Targeted Colorectal Cancer Interventions

Research emphasizes improving survival rates and treatment efficacy through immunotherapy and targeted molecular approaches.

02 Neurological Disorders

Investigations into treatments for Multiple Sclerosis and Alzheimer's Disease, with particular focus on managing associated symptoms and disease progression.

  • MS Long-term Treatment Evaluation
  • Alzheimer's-related Psychosis Management
  • Innovative Therapeutic Approaches

Studies aim to enhance quality of life and develop more effective treatment strategies.

03 Infectious Diseases

Research on treating gram-negative bacterial infections in vulnerable populations, including studies of new antibiotics and treatment protocols.

  • Neonatal Infection Treatment
  • Hospital-acquired Pneumonia
  • Complex Bacterial Infections

Focus on developing safer and more effective treatments for severe infections.

04 Addiction Medicine

Studies examining treatments for alcohol dependence, with emphasis on reducing consumption and maintaining abstinence in high-risk patients.

  • Alcohol Consumption Reduction
  • Maintenance Therapy
  • Risk Level Management

Research aims to improve treatment outcomes for alcohol-dependent individuals.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.